Greenleaf Peter
Director at PTHS; Chief Executive Officer at AUPH; CEO at Sucampo Pharmaceuticals, Inc.
- Sold, on record
- $7.4M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Jul 2, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- PTHSChromocell Therapeutics CorpDirector
- AUPHAurinia Pharmaceuticals Inc.Chief Executive Officer
- Sucampo Pharmaceuticals, Inc.CEO
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- AUPH529,339 shares
- Sucampo Pharmaceuticals, Inc.200,000 shares
- PTHS1,594 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Sucampo Pharmaceuticals, Inc.UnusualNov 29 2016
Sold 200,000 shares at $16.84 ($3.4M)
Greenleaf Peter, CEO
Sold 98.8% of holdings ($3.4M position)2,513 shares leftFirst sale on recordFiling
- 2 Form 4 sale AUPHPlan not statedMar 2 +1919 days
Sold 9,068 shares at $12.01 ($109k)
Greenleaf Peter, Chief Executive Officer
Sold 21.6% of holdings ($505k position)32,967 shares leftFirst sale on recordFiling
- 3 Form 4 sale AUPHPlan not statedMar 2 +365 days
Sold 32,750 shares at $8.94 ($293k)
Greenleaf Peter, Chief Executive Officer
Sold 3.2% of holdings ($9.1M position)982,968 shares leftFiling
- 4 Form 4 sale AUPHNo planMar 6 +370 days
Sold 126,981 shares at $5.60 ($711k)
Greenleaf Peter, Chief Executive Officer
No 10b5-1 planSold 7.7% of holdings ($9.2M position)1.5M shares leftFiling
- 5 Form 4 sale AUPHNo planMar 4 +363 days
Sold 360,540 shares at $7.96 ($2.9M)
Greenleaf Peter, Chief Executive Officer
No 10b5-1 planSold 16.8% of holdings ($17.1M position)1.8M shares leftFiling
- 6 Form 4 sale PTHSRoutineApr 2 +394 days
Sold 797 shares at $20.92 ($17k)
Greenleaf Peter, Director
10b5-1 planSold 3.1% of holdings ($533k position)24,681 shares leftFirst sale on recordFiling
- 7 Form 4 sale PTHSRoutineJul 2 +91 days
Sold 797 shares at $26.14 ($21k)
Greenleaf Peter, Director
10b5-1 planSold 3.2% of holdings ($645k position)23,884 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (7)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | PTHS | Director | Form 4 sale | 797 | $21k | 3.2% | Routine | SEC |
| Apr 2, 2026 | PTHS | Director | Form 4 sale | 797 | $17k | 3.1% | Routine | SEC |
| Mar 4, 2025 | AUPH | Chief Executive Officer | Form 4 sale | 360,540 | $2.9M | 16.8% | No plan | SEC |
| Mar 6, 2024 | AUPH | Chief Executive Officer | Form 4 sale | 126,981 | $711k | 7.7% | No plan | SEC |
| Mar 2, 2023 | AUPH | Chief Executive Officer | Form 4 sale | 32,750 | $293k | 3.2% | Plan not stated | SEC |
| Mar 2, 2022 | AUPH | Chief Executive Officer | Form 4 sale | 9,068 | $109k | 21.6% | Plan not stated | SEC |
| Nov 29, 2016 | Sucampo Pharmaceuticals, Inc. | CEO | Form 4 sale | 200,000 | $3.4M | 98.8% | Unusual | SEC |